AbbVie reports positive phase 2 data for Zumilokibart in atopic dermatitis
AbbVie reports positive phase 2 data for Zumilokibart in atopic dermatitis Seeking Alpha
Covered in this story
Analyst targets on AbbVie
- Citi: $244 → $260 by Jul 2027 · Neutral via GuruFocus
- UBS: $248 → $260 by Jul 2027 · Neutral via GuruFocus
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $ABBV yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on AbbVie →Also covered by 1 other outlet
Dalsna Finance is currently tracking 50 stories mentioning AbbVie, the earliest published 15 May 2026.
Summary aggregated from Seeking Alpha's public RSS feed. The full reporting belongs to Seeking Alpha — please read it on their site.